Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Capecitabine plus bevacizumab therapy Capecitabine:2,000mg/m2 twice daily (orally, day1 after dinner:day8 after breakfast) Bevacizumab:7.5mg/kg day 1 The treatment is repeated every three weeks until disease progression or severe toxicity. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized
创建时间：
2012-09-15
